Newer biologics that target interleukin (IL)-17 and IL-23 are changing the paradigm for psoriasis treatment, report physicians.
Ustekinumab has a higher drug survival rate than adalimumab, etanercept and infliximab, confirms a study of plaque psoriasis patients published in the Journal of Cutaneous Medicine and Surgery.
For psoriasis in difficult locations including the scalp, palms and soles, guselkumab outperformed adalimumab and placebo, shows a study published online in JAMA Dermatology.
This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.
A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.
The July issue of Dermatology Times highlights some newly approved treatments in dermatology including a new wrinkle filler and new treatment for seborrheic keratosis.
Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions.
Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.
The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD.